

News and Deals

1. Souffle Therapeutics: \$135M Series B for cell-targeted RNA medicines | Oct. 13, 2026

Souffle Therapeutics closed an oversubscribed \$135M Series B led by Juvia Group, with TCG Crossover, BB Biotech, Fidelity, Amgen Ventures, ARCH, Bessemer, Leaps by Bayer and other investors participating. The financing will support first clinical studies in FSHD, heart failure, and muscle and metabolic disorders.

HDIG take: RNA therapeutics: the REMEDY platform is designed to deliver oligonucleotides to selected cells outside the liver, addressing a central limitation of the modality. [LINK](#); [LINK](#)

2. Estuary Biotherapeutics: \$93M Series A for targeted kidney gene therapies | Oct. 16, 2026

Estuary Biotherapeutics launched with \$103M in committed capital, including a \$93M Series A led by RA Capital Management. Deep Track, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners and the National Kidney Foundation Innovation Fund joined the round.

HDIG take: Renal genetic medicine: the company is advancing targeted programs for serious kidney diseases, beginning with autosomal dominant polycystic kidney disease. [LINK](#); [LINK](#)

3. Kaigene: \$55M financing for autoimmune antibody therapeutics | Oct. 14, 2026

Kaigene filed a Form D reporting approximately \$55M sold to 22 investors. The Rockville biotech develops next-generation antibody therapeutics for pathogenic antibody-mediated autoimmune diseases and is also building a nanobody-based brain-shuttle platform.

HDIG take: Autoimmune biotech: the financing gives a platform company with active licensing and development partnerships additional capital to advance its antibody pipeline. [LINK](#); [LINK](#)

4. Prolific Machines: \$50M Series B2 for optogenetic biomanufacturing | Oct. 14, 2026

Prolific Machines announced the initial close of a \$50M Series B2 led by Atoms & Bits and Nant Capital. The company also formed a strategic collaboration with NantWorks to apply its light-controlled bioprocess platform across biologics programs.

HDIG take: Biomanufacturing infrastructure: optogenetic control and closed-loop process data could improve yield, quality and consistency as complex biologics move toward production. [LINK](#); [LINK](#)

5. Brellium: \$23M Series B for clinical compliance AI | Oct. 13, 2026

Brellium raised \$23M led by Left Lane Capital and First Round Capital, with Digital Health Venture Partners participating. Its clinical AI reviews patient notes for gaps in care, documentation and payer compliance before billing or audit exposure.

HDIG take: Provider operations: prospective chart review can turn compliance from a retrospective sampling exercise into a continuous workflow tied to care quality and revenue integrity. [LINK](#); [LINK](#)

6. Hurotics: KRW25B Series A for wearable rehabilitation robotics | Oct. 15, 2026

Hurotics raised KRW25B in a Series A led by Atinum Investment, with strategic and institutional investors including Daewoong Pharmaceutical, Naver and Lotte Biologics participating. The company develops soft wearable robots for gait rehabilitation and daily walking assistance.

HDIG take: Rehabilitation technology: the round supports international regulatory work and production for a lightweight exosuit platform spanning clinical recovery and mobility support. [LINK](#); [LINK](#)

7. Confido Health: \$12.5M Series A extension for healthcare operations AI | Oct. 14, 2026

Confido Health added a \$12.5M Series A extension led by Z47, bringing the round to \$22.5M. Its CareOS platform deploys integrated AI agents across appointment scheduling, insurance verification, payment collection and other medical-practice workflows.

HDIG take: Administrative automation: Confido is moving beyond voice agents toward an operating layer that can coordinate multi-step work across fragmented healthcare systems. [LINK](#); [LINK](#)

8. Precision IO Group: \$8.5M financing for interventional oncology robotics | Oct. 16, 2026

Precision IO Group reported approximately \$8.5M in a new securities offering. The company integrates robotics, artificial intelligence and minimally invasive ablation systems to support image-guided cancer treatment.

HDIG take: Interventional oncology: combining robotic control with procedural imaging could standardize complex tumor ablation and broaden access to minimally invasive treatment. [LINK](#); [LINK](#)

9. Otter Health: \$8M Seed for AI-enabled utilization management | Oct. 15, 2026

Otter Health launched with an \$8M Seed round co-led by Fika Ventures and Evidenced, with Slow Ventures, Metrodora, CoFound Partners and others participating. Its EHR-agnostic platform helps payers and providers identify low-value care without relying on traditional prior authorization.

HDIG take: Payer-provider workflow: the model aims to replace adversarial approval processes with real-time, evidence-based guidance embedded closer to the care decision. [LINK](#); [LINK](#)

10. Sensydia: \$6M-plus financing for non-invasive cardiac assessment | Oct. 13, 2026

Sensydia completed an oversubscribed initial close of more than \$6M led by Colle Capital Partners, with Orlando Health Ventures participating. Proceeds will support the ACOUSTIC-1 study and preparations for commercial launch of its Cardiac Performance System.

HDIG take: Cardiovascular diagnostics: the acoustic platform is designed to estimate pulmonary pressures without catheterization, potentially moving advanced hemodynamic assessment into more care settings. [LINK](#); [LINK](#)

11. CrofaBiotech: \$6M Seed for xenotransplantation research | Oct. 14, 2026

Argentina-based CrofaBiotech raised a \$6M Seed round following an earlier \$700K pre-seed. The company is developing genetically modified pigs as a source of kidneys and hearts for potential human transplantation and as models for disease and drug testing.

HDIG take: Transplant biotechnology: the program targets the persistent organ shortage while carrying substantial scientific, regulatory, manufacturing and biosecurity execution risk. [LINK](#); [LINK](#)

12. Collective X Health: \$3.2M pre-seed for women's health intelligence | Oct. 13, 2026

Collective X Health emerged from stealth with a \$3.2M pre-seed round co-led by Council Capital and Anthemis Female Innovators Lab Fund. Its B2B platform licenses research-backed female physiology data and insights to health, wellness and performance products.

HDIG take: Women's health data: the company is building an evidence layer intended to reduce bias and improve the accuracy of products designed around female physiology. [LINK](#); [LINK](#)

Upcoming Healthcare Events

Date	Event	Location	Why it matters
Oct. 26-28, 2026	Precision Health Information Network Summit 2026	Nashville, TN	Action-oriented summit on the data, digital infrastructure, reimbursement and implementation barriers to precision medicine at scale.
Nov. 5, 2026	UK Healthcare Innovation Summit 2026	London, United Kingdom	Bamberg Health convenes health-system leaders around digital innovation, AI, interoperability, workforce resilience and transformation.
Nov. 10, 2026	Becker's Webinar: Agentic AI Across Health Systems	Virtual	Leaders from ECU Health, UTMB and Hawaii Pacific Health review live clinical, operational and administrative AI-agent deployments.
Nov. 15-18, 2026	HLTH USA 2026	The Venetian, Las Vegas, NV	Healthcare innovation gathering spanning AI, care delivery, digital health, diagnostics, pharma and startups. HDIG will have a booth on the show floor.